Renbio

Executive Summary

RenBio is a privately held biotechnology company based in Cambridge, MA, developing a novel DNA-based platform for in vivo production of therapeutic proteins and antibodies. Its core 'Make Your Own (MYO) Technology' uses intramuscular injection and electroporation to deliver genetic blueprints directly into muscle cells, enabling the patient's own body to produce the therapeutic agent. This approach aims to enhance durability, simplify dosing, and reduce costs compared to traditional biologics manufacturing. Founded in 2018, RenBio focuses on addressing infectious diseases, obesity, and other conditions where sustained levels of therapeutic proteins could transform treatment paradigms. The platform's potential to democratize access to advanced antibody therapies makes it a compelling player in the biologics space, though it remains at an early stage without disclosed funding or clinical data.

Upcoming Catalysts (preview)

• H2 2026IND Filing for Lead Program (e.g., infectious disease or obesity)40% success
• TBDStrategic Partnership or Licensing Deal with Larger Pharma50% success
• Q3 2026Preclinical Proof-of-Concept Data Publication70% success